Table 2.
Clinical and Pathological Characteristics Associated with Tumor PD-L1 Positivity in Mismatch Repair Intact Grade 2 Endometrial Endometrioid Adenocarcinoma
| Variable | Tumor PD-L1 negative (69/132; 52%) |
Tumor PD-L1 positive (63/132; 48%) |
p-value |
|---|---|---|---|
| Age, n, years | |||
| Mean (SD) | 59 (12) | 59 (11) | 0.857 |
| Median (Minimum-Maximum) | 60 (27-82) | 60 (30-88) | |
| Tumor size (mm), n (%) | |||
| Mean (SD) | 43 (26) | 47 (27) | 0.202 |
| Median (Minimum- Maximum) | 35 (13-127) | 43 (10-145) | |
| Tumor stage, n (%) | |||
| I or II | 66 (96) | 51 (81) | 0.012 |
| III or IV | 3 (4) | 12 (19) | |
| Any myometrial invasion, n (%) | |||
| Yes | 44 (64) | 51 (81) | 0.028 |
| No | 25 (36) | 12 (19) | |
| Myometrial invasion present and ≥50%, n (%) | |||
| Yes | 7 (16) | 23 (45) | 0.002 |
| No | 37 (84) | 28 (55) | |
| Not applicable (no myometrial invasion) | 25 | 12 | |
| LVSI, n (%) | |||
| Yes | 8 (12) | 22 (35) | 0.001 |
| No | 61 (88) | 41 (65) | |
| Metastasis to pelvic lymph nodes, n (%) | |||
| Yes | 2 (5) | 9 (18) | 0.105 |
| No | 36 (95) | 41 (82) | |
| Metastasis to para-aortic lymph nodes, n (%) | |||
| Yes | 0 | 5 (15) | 0.156 |
| No | 17 (100) | 29 (85) | |
| PTEN IHC, n (%) | |||
| Positive | 42 (61) | 23 (37) | 0.012 |
| Heterogeneous | 2 (3) | 6 (10) | |
| Negative | 25 (36) | 34 (54) | |
| CD3 (mean cells/mm2, SD) | |||
| Overall | 800 (470) | 989 (642) | 0.110 |
| Hotspot | 1287 (688) | 1647 (622) | 0.024 |
| Periphery | 729 (436) | 1087 (746) | 0.003 |
| Center | 811 (516) | 920 (627) | 0.367 |
| CD8 (mean cells/mm2, SD) | |||
| Overall | 398 (293) | 571 (548) | 0.137 |
| Hotspot | 652 (441) | 950 (733) | 0.017 |
| Periphery | 383 (275) | 654 (604) | 0.010 |
| Center | 379 (319) | 508 (548) | 0.323 |
| CD68 (mean cells/mm2, SD) | |||
| Overall | 176 (158) | 179 (116) | 0.315 |
| Hotspot | 286 (241) | 308 (182) | 0.118 |
| Periphery | 157 (152) | 179 (120) | 0.058 |
| Center | 193 (183) | 183 (131) | 0.696 |